Indication
Advanced prostatic carcinoma
Advanced prostatic carcinoma refers to a malignant epithelial neoplasm of the prostate gland that has progressed beyond localized, organ-confined disease. Read more about Advanced prostatic carcinoma
92 drugs 64 manufacturers
Drugs that treat it
Common Advanced prostatic carcinoma therapies.
TRELSTAR (triptorelin pamoate)
ESTRADIOL
ESTRACE (estradiol)
ELIGARD (leuprolide acetate)
FIRMAGON (degarelix acetate)
TRELSTAR (triptorelin pamoate)
TRELSTAR (triptorelin pamoate)
ELIGARD (leuprolide acetate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAdvanced prostatic carcinoma refers to a malignant epithelial neoplasm of the prostate gland that has progressed beyond localized, organ-confined disease.
Primarily affecting older adult males, this clinical state encompasses locally advanced tumors involving regional pelvic structures or lymph nodes, as well as distant metastatic dissemination most commonly to the axial skeleton and visceral organs.
Pathophysiologically, the disease is driven by aberrant androgen receptor signaling and progressive genomic instability, leading to invasive growth, elevated serum prostate-specific antigen levels, and a clinical continuum spanning hormone-sensitive, biochemically recurrent, and castration-resistant states.
- nih.gov
Advanced prostatic carcinoma refers to a malignant epithelial neoplasm of the prostate gland that has progressed beyond localized, organ-confined disease Primarily affecting older adult males, this clinical state encompasses locally advanced tumors involving regional pelvic structures or lymph nodes, as well as distant metastatic dissemination most commonly to the axial skeleton and visceral organs Pathophysiologically, the disease is driven by aberrant androgen receptor signaling and progressiv...
- clevelandclinic.org
Advanced prostatic carcinoma refers to a malignant epithelial neoplasm of the prostate gland that has progressed beyond localized, organ-confined disease Primarily affecting older adult males, this clinical state encompasses locally advanced tumors involving regional pelvic structures or lymph nodes, as well as distant metastatic dissemination most commonly to the axial skeleton and visceral organs
- zerocancer.org
Pathophysiologically, the disease is driven by aberrant androgen receptor signaling and progressive genomic instability, leading to invasive growth, elevated serum prostate-specific antigen levels, and a clinical continuum spanning hormone-sensitive, biochemically recurrent, and castration-resistant states
- nih.gov
Pathophysiologically, the disease is driven by aberrant androgen receptor signaling and progressive genomic instability, leading to invasive growth, elevated serum prostate-specific antigen levels, and a clinical continuum spanning hormone-sensitive, biochemically recurrent, and castration-resistant states
Personalize your experience
Follow Advanced prostatic carcinoma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.